RU2318506C1 - Method for restricting the necrosis area with roxytromycin while modeling coronary occlusion myocardial infarction in animals - Google Patents

Abstract

FIELD: medicine, experimental cardiology.

SUBSTANCE: the present innovation deals with restricting the necrosis area in the course of experimental coronary occlusion myocardial infarction due to intragastric introduction of roxytromycin at the dosage of 30 mg/kg 15 min before coronary occlusion. The innovation provides significant decrease of the necrosis area due to cardioprotector action of roxytromycin.

EFFECT: higher efficiency.

1 ex, 1 tbl

Description

The invention relates to medicine, namely to experimental pharmacology and cardiology.

The prototype of this invention is: patent No. 2226101. "A method of limiting the necrosis zone when modeling coronary occlusion myocardial infarction in animals with a reduced antioxidant background."

The main disadvantage of this method is that azithromycin only works with a low antioxidant background of the body.

To eliminate this drawback, we used the macrolide antibiotic roxithromycin at a concentration of 30 mg / kg, which acts with any antioxidant background of the body, effectively prevents the development of post-infarction pneumonia, and also specifically accumulates in neutrophils and is transported to the zone of aseptic inflammation, creating high intracellular concentrations there, and, thus, it limits the zone of necrosis and increases the survival of animals.

The technical result of the invention is a method for limiting the zone of necrosis of the infarcted myocardium, including the use of roxithromycin, which belongs to the antibiotics of the macrolide group.

The technical result is achieved due to the fact that in order to limit the area of necrosis, the drug roxithromycin is administered, which acts regardless of the antioxidant background of the body. We used a dose of 30 mg / kg roxithromycin.

The method was carried out as follows.

The experiments were carried out on white rats male Wistar line weighing 350-450 g

Under anesthesia (etaminal sodium 50 mg / kg), coronary occlusion myocardial infarction was reproduced (A.X. Kogan, 1979). 15 minutes before coronary occlusion, roxithromycin was administered intragastrically at a dose of 30 mg / kg.

The cardioprotective effect of the studied drug was evaluated by comparing the size of the necrosis zone between the experimental group of animals without treatment, as well as with the treatment of the studied drug. The effects of roxithromycin on mortality of laboratory animals in the first days after surgery were also evaluated. The experiment did not take animals that died in the first 15 minutes after coronary occlusion.

When statistical data processing was calculated, the average value, the standard deviation. Differences were considered significant at p <0.05.

Example

On white rats of males of the Wistar line, coronary occlusal myocardial infarction was simulated. 15 minutes before coronary occlusion, roxithromycin was administered intragastrically at a dose of 30 mg / kg. The drug was administered once. After 24 hours, the number of dead animals was determined, and the size of the zone of left ventricular necrosis was measured with its planimetric determination.

To determine the objectives of the invention, the following groups were formed:

- control (n = 10);

- roxithromycin 30 mg / kg (n = 10).

The results are presented in table No. 1.

Table number 1.
Values of mortality and% necrosis of the left ventricle of rats when modeling coronary occlusion myocardial infarction on the 2nd day against the background of the use of roxithromycin.
(M ± m;%, n = 10) Experimental group % zone of necrosis % mortality The control 39.1 ± 1.2 33.3 ± 1.2 Roxithromycin 30 mg / kg 26.9 ± 1.8 * 12.5 ± 1.5 * * at p <0.05 in comparison with the control group

Based on the data obtained, it follows that the macrolide antibiotic roxithromycin used significantly improved the survival of animals in the first day after myocardial infarction compared with the control group. At the same time, the zone of aseptic necrosis of the left ventricle significantly decreased when taking this drug.

Thus, the results indicate a pronounced cardioprotective effect of roxithromycin.

Claims (1)

A method for limiting the necrosis zone when modeling coronary occlusal myocardial infarction in Wistar rats, characterized in that the animals are injected with a macrolide drug roxithromycin at a dose of 30 mg / kg.